Friday, 20 February 2015
Novo Nordisk has positive trial results for oral GLP-1 drug, shares jump
COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk, the world's biggest insulin maker, said on Friday it had received positive results from a phase 2 trial of an oral version of a long-acting GLP-1 for treatment of people with type 2 diabetes.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment